Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search


MARS Bioimaging to Position Itself for Series A Fundraising

February 25, 2014

MARS Bioimaging Raises over $500,000 to Position Itself for Series A Fundraising

Christchurch, February 25, 2014 — MARS Bioimaging raises more than NZ$500,000 in a capital financing led by Powerhouse Ventures (powerHouse).

MARS Bioimaging (MBI) intends to utilise the investment to strengthen the management and development teams prior to Series A fundraising later in 2014.

Originally spun out from the University of Canterbury in 2007, MBI is now releasing its first commercial grade xray scanners after successfully validating the groundbreaking technology with high profile medical research institutes.

The Director of Research & Innovation at the University of Canterbury, Dr Nigel Johnson, said “It is exciting to see worldleading physics and biomedical research culminating in a sophisticated medical instrument. This additional capital will help MBI’s machines contribute to health improvements globally while delivering economic benefits to New Zealand.”

MBI provides in vivo colour xray imaging, using spectral computed tomography (CT) technology developed by the CERNbased Medipix3 Collaboration and University of Canterbury researchers. University of Otago, Christchurch is a key partner.

Spectral CT can provide images of bone, soft tissue, calcifications and injected contrast agents. This decomposition ability has many advantages for detection, diagnosis and treatment of major diseases such as cancer and heart diseases.

MBI CEO, Professor Phil Butler, notes “MBI’s objective is to become the preclinical imaging company of choice for research organisations and drug development companies, and a key component supplier to the clinical human imaging market.”

The preclinical imaging market is estimated at US$1.7 billion and the human imaging market at US$28 billion.

MARS Bioimaging won the Canterbury Regional Deloitte Fast 50 Rising Star award in 2013.

powerHouse’s Managing Partner Stephen Hampson, said “We are delighted to announce the successful capital raise that will allow MBI to accelerate its entry into this exciting high growth sector.”

powerHouse develops intellectual property based businesses from innovations sourced mainly from its university partners and research institutes. powerHouse offers more than traditional seed and startup capital, with ongoing access to business incubation, HR recruitment and networks.


© Scoop Media

Business Headlines | Sci-Tech Headlines


Welcome Home: Record High Migration Stokes 41-Year High Population Growth

New Zealand annual net migration hit a new high in October as more people arrived from than departed for Australia for the first time in more than 20 years. More>>


Citizens' Advice Bureau: Report Shows Desperate Housing Situation Throughout NZ

CAB's in-depth analysis of over 2000 client enquiries about emergency accommodation shows vulnerable families, pregnant women and children living in cars and garages, even after seeking assistance from the Ministry of Social Development and Housing New Zealand. More>>


Speaking For The Bees: Greens Call For Neonicotinoid Pesticide Ban

The National Government should ban the use of controversial pesticides called neonicotinoids after evidence has revealed that even at low doses they cause harm to bee populations, the Green Party said today. More>>


Science Awards: NZAS Celebrate NZ Scientific Achievements

The Marsden Medal is awarded for a lifetime of outstanding service to the cause or profession of science, in recognition of service rendered to the cause or profession of science in the widest connotation of the phrase. This year’s medal is awarded to Dr Mike Andrews. More>>


Court Rules: Affco 'Unlawfully' Locked Out Meat Workers

The note says the full court found for the plaintiffs, "that is that the defendant locked out the second plaintiffs unlawfully and that it breached s 32 of the Act by acting otherwise than in good faith towards the plaintiffs while collective bargaining was still going on." More>>


Get More From Scoop

Search Scoop  
Powered by Vodafone
NZ independent news